Abstract | BACKGROUND: METHODS: The mice were divided into the following groups: combination treatment (n = 21), olmesartan treatment alone (n = 23), azelnidipine treatment alone (n = 29) or untreated (n = 26). Mean blood pressure and kidney weight were measured at 4 and 8 weeks after the treatment. Renal expression of angiotensin II, gp91, nitrotyrosine and endothelial NO synthase (eNOS) were examined by immunostaining. In addition, extracellular signal-regulated kinase activation was evaluated by Western blotting. RESULTS: CONCLUSION:
|
Authors | Chiaki Tanifuji, Yusuke Suzuki, Wong Mu Geot, Satoshi Horikoshi, Hisahide Takahashi, Yasuhiko Tomino |
Journal | Kidney & blood pressure research
(Kidney Blood Press Res)
Vol. 32
Issue 4
Pg. 239-49
( 2009)
ISSN: 1423-0143 [Electronic] Switzerland |
PMID | 19752573
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | (c) 2009 S. Karger AG, Basel. |
Chemical References |
- Angiotensin II Type 1 Receptor Blockers
- Calcium Channel Blockers
- Dihydropyridines
- Imidazoles
- Tetrazoles
- Angiotensin II
- Azetidinecarboxylic Acid
- olmesartan
- Nitric Oxide Synthase Type III
- NADPH Oxidases
- Extracellular Signal-Regulated MAP Kinases
- azelnidipine
|
Topics |
- Angiotensin II
(metabolism)
- Angiotensin II Type 1 Receptor Blockers
(therapeutic use)
- Animals
- Azetidinecarboxylic Acid
(analogs & derivatives, therapeutic use)
- Blotting, Western
- Calcium Channel Blockers
(therapeutic use)
- Dihydropyridines
(therapeutic use)
- Drug Synergism
- Drug Therapy, Combination
- Extracellular Signal-Regulated MAP Kinases
(metabolism)
- Fibrosis
- Imidazoles
(therapeutic use)
- Immunohistochemistry
- Kidney
(pathology)
- Mice
- NADPH Oxidases
(metabolism)
- Nitric Oxide Synthase Type III
(biosynthesis)
- Polycystic Kidney Diseases
(drug therapy, pathology)
- Tetrazoles
(therapeutic use)
|